Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
Susanna Edith Medellín-GaribayNadia Hernández-VillaLourdes Cecilia Correa-GonzálezMiriam Nayeli Morales-BarragánKarla Paulina Valero-RiveraJuan Eduardo Reséndiz-GalvánJuan José Ortiz-ZamudioRosa Del Carmen Milán-SegoviaSilvia Romano-MorenoPublished in: Cancer chemotherapy and pharmacology (2019)
The establishment of MTX dosing criteria in children with ALL should be adjusted based on the BSA of each patient to optimize oncological therapy and reduce the development of adverse effects. Therapeutic drug monitoring is an essential tool to individualize MTX doses to reduce toxicity and improve patients' outcomes.
Keyphrases
- acute lymphoblastic leukemia
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- oxidative stress
- peritoneal dialysis
- case report
- high dose
- prostate cancer
- stem cells
- low dose
- allogeneic hematopoietic stem cell transplantation
- skeletal muscle
- robot assisted
- weight loss
- minimally invasive